4.8 Article

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression

期刊

NATURE COMMUNICATIONS
卷 9, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-018-02851-7

关键词

-

资金

  1. SINF
  2. MDACC grant
  3. NIH Skin Cancer SPORE [P50 CA 093459]
  4. NCI [P50 CA140388]
  5. NIH Clinical Research Loan Repayment Program
  6. National Institutes of Health (NIH/NCATS) [UH3TR00943]
  7. NIH/NCI [R01-CA182905]
  8. UT MD Anderson Cancer Center SPORE in Melanoma grant from NIH/NCI [P50 CA093459]
  9. AIM at Melanoma Foundation
  10. Miriam Mulva research fund
  11. Jim Mulva research fund
  12. CLL Moonshot Flagship project

向作者/读者索取更多资源

Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据